RFK Jr.'s Chief HHS Spokesperson Resigns Over Flavored Vapes Pressure
Rich Danker, HHS Secretary Robert F. Kennedy Jr.'s chief spokesperson, resigned citing irreconcilable differences with efforts to advance electronic cigarette flavors that could cause children to become addicted.
Objective Facts
Rich Danker, HHS Secretary Robert F. Kennedy Jr.'s chief spokesperson, resigned on Wednesday citing irreconcilable differences with efforts to advance electronic cigarette flavors that could cause children to become addicted. He left his role as assistant secretary for public affairs a day after FDA Commissioner Marty Makary officially stepped down. In his resignation letter to President Trump, Danker wrote that senior HHS officials in the immediate office of the secretary had sought FDA marketing approval of cigarette flavors that would appeal to children and expose them to nicotine addiction, lung damage and higher risk of cancer. Makary left office after clashing with the White House over pressure from Trump to authorize the flavored vapes. These back-to-back resignations leave HHS with at least three major leadership vacancies, including a permanent FDA Commissioner, Surgeon General, and Communications Chief, with the CDC Director position also remaining unfilled.
Left-Leaning Perspective
Common Dreams reported that the resignation of a pair of top health officials has brought to light efforts by the president to help Big Tobacco executives and lobbyists sell addictive flavored e-cigarettes that could be marketed to children, as the FDA issued new guidance allowing cigarette makers to begin marketing and selling fruit- and candy-flavored vape products on store shelves, which were banned under previous administrations. MSNBC's Rachel Maddow blog reported that tobacco industry executives and lobbyists leaned on Donald Trump and his team to expand access to the flavored vaping products, and by some accounts, the president, convinced that young MAGA voters care about the issue, ended up personally upbraiding the FDA commissioner on the matter. Protect Our Care's healthcare advocacy group stated that Makary's ouster and replacement 'all but guarantees an FDA further consumed by chaos and driven by the wish lists of special interests that want profits put before public health.' Jeremy Funk, deputy director of Protect Our Care's Public Health Watch team, argued that 'Donald Trump's fury at FDA head Makary was motivated by gross political opportunism and fat checks from the big vape industry,' and 'Trump could not care less about the health consequences and costs of giving teenagers access to addictive flavored poison if it means his tobacco industry donors can make record profits.' Public health advocates strongly disagree with the FDA's rationale, warning that fruity flavors are proven to attract young people, and health groups argue that expanding flavored product approvals undermines years of youth anti-vaping efforts. Democratic senator Dick Durbin of Illinois and Republican senator Susan Collins of Maine co-signed a letter expressing concern that the approval's public health risks outweighed any benefits, noting that 'FDA should not ignore the basic reality that kids are drawn to what flavors are most available to them.' Left-leaning coverage emphasizes how the resignations reveal a fundamental policy clash inside one of the most important health agencies in the world—one that could shape the future of nicotine regulation in the United States. However, much of the left's coverage downplays that some anti-smoking researchers acknowledge potential harm-reduction benefits of vaping for adult smokers, instead focusing primarily on youth addiction risks and industry lobbying pressure.
Right-Leaning Perspective
The Washington Examiner's opinion commentary stated that 'the Trump administration is pushing back against prohibition' and noted that 'the White House is pushing to allow more vape flavors on the market' while 'FDA Commissioner Marty Makary opposes the move.' The commentary argued that 'every day, millions of Americans rely on harm-reduction products to kick the deadly habit of cigarette smoking,' the FDA 'has been anything but helpful in facilitating that process,' and 'the Trump administration and the FDA could save countless lives by reversing course and allowing more reduced-risk products on the market.' Nicotine Insider reported that parts of the nicotine industry view the recent moves as 'a long-overdue shift toward a more functional PMTA framework, following years of regulatory bottlenecks and widespread unauthorized-market growth.' Right-leaning analysis emphasizes that 'reduced-risk products are extraordinarily effective in getting smokers to quit cigarettes,' with evidence showing 'e-cigarette availability results in increased quit rates compared to nicotine replacement therapy,' and that 'flavored vapes are especially effective in weaning smokers off of cigarettes, which is why flavor bans tend to increase cigarette smoking.' Glas CEO Sean Greenbaum's statement—widely cited by supporters—argued that 'our data show that flavored products can play an important role in helping adult smokers move away from combustible cigarettes,' and the acting director of the FDA's Center for Tobacco Products, Bret Koplow, called device access restrictions a 'potential game changer' and noted that the technology could 'help to enable availability of an expanded array of flavored options for adults who smoke.' Right-leaning coverage emphasizes that Danker and Makary did not blame Trump directly and frames the issue as a legitimate debate between harm-reduction advocates and restrictionists, rather than primarily as a capitulation to tobacco industry pressure. However, the right's framing tends to downplay or omit the specific evidence of Trump's personal involvement in forcing the approvals against FDA scientists' concerns, and it does not substantively address the concern that age-verification technology may be easily circumvented.
Deep Dive
The specific angle of this story is not about the broader vaping debate or health policy generally, but rather about Rich Danker's resignation—his decision to leave his position and the pressure from Trump administration officials over flavored vape authorization. The story's essential tension is whether this represents a principled whistle-blower moment or an official whose views were out of step with his administration's policy direction. The context: tobacco industry executives and lobbyists leaned on Donald Trump and his team to expand access to flavored vaping products, and by some accounts, the president, convinced that young MAGA voters care about the issue, ended up personally upbraiding the FDA commissioner on the matter. Makary had opposed broader flavored vape authorizations and tried to slow or block approvals for fruit-flavored products from Glas Inc., but officials overruled him, resulting in two of the most senior health officials in the country resigning within 24 hours over the exact same policy dispute. Notably, Danker's resignation letter cited that the new FDA policy contradicts guidance issued on March 9, 2026, regarding flavored ENDS products and youth risk that carried White House support, thus the new approvals appear to conflict with the administration's own prior public health position. What each perspective gets right: The left correctly identifies that Trump personally pressured the FDA to approve flavored vapes against internal scientific reservations, and that the policy shift contradicts the administration's own March guidance warning against flavored products. The right correctly points out that some researchers acknowledge vaping's potential as a smoking-cessation tool and that Danker and Makary did not directly blame Trump, instead attributing pressure to unnamed "senior HHS officials." What each omits: The left downplays that some anti-smoking researchers genuinely disagree about whether youth risks outweigh adult harm-reduction benefits, and it does not substantively address whether age-verification technology might work. The right does not directly confront the specific evidence of Trump's personal involvement in forcing a policy reversal against FDA staff recommendations, focusing instead on the general principle of regulatory reform. What to watch next: Pressure is growing from health advocates, lawmakers, and former officials who oppose the flavored vape policy. The Trump administration has not yet named a replacement for Danker, and similarly, a new FDA Commissioner has not been announced since Makary's departure. The immediate stakes include whether the HHS will find leadership willing to implement the flavored vape policy without internal dissent, and whether the approvals will face legal challenge or congressional scrutiny. The broader question is whether the Danker and Makary resignations represent an isolated personnel dispute or signal deeper dysfunction within the department during a period of significant regulatory upheaval.